Susquehanna Fundamental Investments’s Design Therapeutics DSGN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$182K	Buy	+12,553	New	+$157K	﹤0.01%	700

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna Fundamental Investments's DSGN Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Design Therapeutics (DSGN) in Q2 2026: 12,553 shares worth $182K. The stake represents ﹤0.01% of the portfolio and ranks #700 among its holdings.

137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Susquehanna Fundamental Investments held 12,553 shares of Design Therapeutics worth $182K as of Q2 2026.
Design Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
Design Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #700 holding.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.